Obstetrics & Gynaecology

Top Medical News
Does LMWH improve live birth rate in women with inherited thrombophilia and miscarriage history?
Roshini Claire Anthony, 16 hours ago

The use of low-molecular-weight heparin (LMWH) during pregnancy did not increase the likelihood of live birth compared with standard surveillance in women with inherited thrombophilia who have experienced multiple miscarriages, according to a multinational study presented at ASH 2022.

Buprenorphine use during pregnancy linked to better neonatal outcomes
Elaine Soliven, 21 hours ago
The use of buprenorphine during pregnancy appears to be associated with a lower risk of adverse neonatal outcomes compared with methadone use. However, adverse maternal outcomes are similar for both therapies, according to a recent study.
Letrozole outperforms clomiphene citrate for ovulation induction
Yesterday
The use of letrozole for inducing ovulation in women with infertility and polycystic ovarian syndrome (PCOS) appears to yield improvements in ovulation, pregnancy, and live-birth rates as compared with clomiphene citrate, according to a study.
Ospemifene improves vaginal microbiome of women with vulvovaginal atrophy
29 Jan 2023
Women with vulvovaginal atrophy exhibit a less favourable vaginal microbiome than healthy postmenopausal women, but ospemifene may restore vaginal health by reducing potentially harmful bacteria, as shown in a study.
Are children conceived with assisted technologies at risk for cardiometabolic events?
27 Jan 2023
Children conceived by their parents through non-in vitro fertilization fertility treatment show no metabolic difference from those conceived spontaneously, according to a study.
Diminished ovarian reserve linked to pre-eclampsia, placental vascular lesions
26 Jan 2023
Among pregnant women who conceived via in vitro fertilization (IVF), diminished ovarian reserve appears to contribute to a higher incidence of pre-eclampsia and multiple placental vascular lesions of foetal origin, as reported in a study.
Allergy testing during pregnancy could avoid unnecessary antibiotic exposure
26 Jan 2023
Women with nonalcoholic fatty liver disease (NAFLD), despite having a normal weight, remains at greater risk of adverse pregnancy outcomes, reveals a study.
Special Reports
Product Highlight - Talzenna
13 Sep 2022
Talazoparib 0.25 mg hard cap
Management of recurrent implantation failure during the COVID-19 pandemic
Dr. Ameet Patki, Dr. Prakash Mayandi, 22 Mar 2022
Recurrent implantation failure (RIF) refers to the failure to achieve a clinical pregnancy after three in vitro fertilization (IVF) attempts with at least four good-quality embryos. RIF leaves couples frustrated and desperate for answers and is challenging for clinicians to handle, compounded by the impact of the COVID-19 pandemic restrictions. Two experts, Dr Ameet Patki, Medical Director of Fertility Associates Mumbai and Hon Assoc Prof at KJ Somaiya Medical College & Hospital, India, and Dr Prakash Mayandi, Metro IVF Fertility Centre, Kuala Lumpur, Malaysia, weigh in with their views on managing RIF during the COVID-19 pandemic.
Product Highlight - Evenity
01 Dec 2021
Romosozumab 105 mg/1.17 mL soln for inj
The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib
Dr. Wong Seng Weng, Dr. Lee Guek Eng, 19 Mar 2021
In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.
Expert consensus: Patient profile should guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Gangliosides and cognition: An appraisal of the evidence
01 Sep 2018

Gangliosides and docosahexaenoic acid (DHA) play critical roles in early childhood brain development. 

Conference Reports
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
Roshini Claire Anthony, 20 Jan 2023

Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.

Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
Roshini Claire Anthony, 08 Jan 2023

The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.

Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
Roshini Claire Anthony, 05 Jan 2023

Young breast cancer survivors could safely temporarily stop adjuvant endocrine therapy (ET) to attempt pregnancy, according to primary results of the POSITIVE* trial presented at SABCS 2022.

Updated monarchE results show improved treatment effects of abemaciclib for breast cancer
Audrey Abella, 28 Dec 2022
In the preplanned overall survival (OS) interim analysis of the monarchE study, the combination of abemaciclib and endocrine therapy (ET) continued to provide benefit for individuals with HR+, HER2–, node-positive, high-risk early breast cancer even after completion of therapy.
EMERALD updates highlight therapeutic potential of elacestrant for ER+/HER2– mBC
Audrey Abella, 20 Dec 2022
In the updated analysis of the phase III EMERALD trial, the next-generation oral SERD* elacestrant continued to show favourable signals for the treatment of ER+/HER2– metastatic breast cancer (mBC).
Does frozen embryo transfer up hypertension risk during pregnancy?
Roshini Claire Anthony, 25 Sep 2022

The risk of hypertensive disorders in pregnancy (HDP) is increased following assisted reproductive technology (ART) using frozen embryo transfer (FET) compared with after fresh embryo transfer or natural conception, according to results of a study presented at ESHRE 2022.

Probiotic supplement has no effect on vaginal microbiome in women undergoing IVF
Roshini Claire Anthony, 04 Sep 2022

A 10-day course of probiotics containing two strains of lactobacilli does not appear to improve vaginal microbiome quality in women planning to undergo in vitro fertilization (IVF), according to results of a recent study presented at ESHRE 2022.